These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 18044015)

  • 1. The Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial in perspective.
    Sauer WH; Bristow MR
    J Interv Card Electrophysiol; 2008 Jan; 21(1):3-11. PubMed ID: 18044015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: clinical background, rationale, design, and implementation.
    Sweeney MO; Ellenbogen KA; Miller EH; Sherfesee L; Sheldon T; Whellan D
    J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1295-8. PubMed ID: 17081208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial.
    Feldman AM; de Lissovoy G; Bristow MR; Saxon LA; De Marco T; Kass DA; Boehmer J; Singh S; Whellan DJ; Carson P; Boscoe A; Baker TM; Gunderman MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2311-21. PubMed ID: 16360064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of left ventricular lead location on outcomes in the COMPANION study.
    Saxon LA; Olshansky B; Volosin K; Steinberg JS; Lee BK; Tomassoni G; Guarnieri T; Rao A; Yong P; Galle E; Leigh J; Ecklund F; Bristow MR
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):764-8. PubMed ID: 19298563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of medical therapy, pacing and defibrillation in heart failure (COMPANION) trial terminated early; combined biventricular pacemaker-defibrillators reduce all-cause mortality and hospitalization.
    Salukhe TV; Francis DP; Sutton R
    Int J Cardiol; 2003 Feb; 87(2-3):119-20. PubMed ID: 12559527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The current role of cardiac resynchronization therapy in reducing mortality and hospitalization in heart failure patients: a meta-analysis from clinical trials.
    Rossi A; Rossi G; Piacenti M; Startari U; Panchetti L; Morales MA
    Heart Vessels; 2008 Jul; 23(4):217-23. PubMed ID: 18649051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pacing for soft indications on mortality and heart failure in the dual chamber and VVI implantable defibrillator (DAVID) trial.
    Kutalek SP; Sharma AD; McWilliams MJ; Wilkoff BL; Leonen A; Hallstrom AP; Kudenchuk PJ;
    Pacing Clin Electrophysiol; 2008 Jul; 31(7):828-37. PubMed ID: 18684279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early mortality in implantable cardioverter defibrillator patients: from randomized controlled trials to real life.
    Köbe J; Eckardt L
    Europace; 2009 Jun; 11(6):694-6. PubMed ID: 19470594
    [No Abstract]   [Full Text] [Related]  

  • 9. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial.
    Bristow MR; Saxon LA; Feldman AM; Mei C; Anderson SA; DeMets DL
    JACC Heart Fail; 2016 Jul; 4(7):521-535. PubMed ID: 27289408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial.
    Carson P; Anand I; O'Connor C; Jaski B; Steinberg J; Lwin A; Lindenfeld J; Ghali J; Barnet JH; Feldman AM; Bristow MR
    J Am Coll Cardiol; 2005 Dec; 46(12):2329-34. PubMed ID: 16360067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of cardiac resynchronization therapy with or without a defibrillator on survival and hospitalizations in patients with New York Heart Association class IV heart failure.
    Lindenfeld J; Feldman AM; Saxon L; Boehmer J; Carson P; Ghali JK; Anand I; Singh S; Steinberg JS; Jaski B; DeMarco T; Mann D; Yong P; Galle E; Ecklund F; Bristow M
    Circulation; 2007 Jan; 115(2):204-12. PubMed ID: 17190867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry.
    Gadler F; Valzania C; Linde C
    Europace; 2015 Jan; 17(1):69-77. PubMed ID: 25336667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of left ventricular lead position on clinical outcomes in the COMPANION study: does placement really matter?
    Freedberg NA
    J Cardiovasc Electrophysiol; 2009 Jul; 20(7):769-72. PubMed ID: 19460075
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial.
    Anand IS; Carson P; Galle E; Song R; Boehmer J; Ghali JK; Jaski B; Lindenfeld J; O'Connor C; Steinberg JS; Leigh J; Yong P; Kosorok MR; Feldman AM; DeMets D; Bristow MR
    Circulation; 2009 Feb; 119(7):969-77. PubMed ID: 19204305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable cardioverter defibrillators: do women fare worse than men? Gender comparison in the INTRINSIC RV trial.
    Russo AM; Day JD; Stolen K; Mullin CM; Doraiswamy V; Lerew DL; Olshansky B
    J Cardiovasc Electrophysiol; 2009 Sep; 20(9):973-8. PubMed ID: 19470037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of PR Interval on Outcomes Following Cardiac Resynchronization Therapy: A Secondary Analysis of the COMPANION Trial.
    Lin J; Buhr KA; Kipp R
    J Cardiovasc Electrophysiol; 2017 Feb; 28(2):185-191. PubMed ID: 27885751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of cardiac resynchronization therapy in combination with an implantable cardioverter defibrillator (CRT-D) for the treatment of chronic heart failure from a German health care system perspective.
    Aidelsburger P; Grabein K; Klauss V; Wasem J
    Clin Res Cardiol; 2008 Feb; 97(2):89-97. PubMed ID: 17955159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort.
    Varma N; Mittal S; Prillinger JB; Snell J; Dalal N; Piccini JP
    J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28490521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of sudden cardiac death and appropriate shock in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Trial.
    Saxon LA; Bristow MR; Boehmer J; Krueger S; Kass DA; De Marco T; Carson P; DiCarlo L; Feldman AM; Galle E; Ecklund F
    Circulation; 2006 Dec; 114(25):2766-72. PubMed ID: 17159063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
    Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
    Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.